GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Revenue per Share

BRNS (Barinthus Biotherapeutics) Revenue per Share : $0.38 (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Revenue per Share?

Barinthus Biotherapeutics's revenue per share for the three months ended in Dec. 2024 was $0.00. Barinthus Biotherapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.38.

During the past 12 months, the average Revenue Per Share Growth Rate of Barinthus Biotherapeutics was 1709.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 236.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Barinthus Biotherapeutics's Revenue per Share or its related term are showing as below:

BRNS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -94.1   Med: 71.05   Max: 236.2
Current: 236.2

During the past 6 years, Barinthus Biotherapeutics's highest 3-Year average Revenue Per Share Growth Rate was 236.20% per year. The lowest was -94.10% per year. And the median was 71.05% per year.

BRNS's 3-Year Revenue Growth Rate is ranked better than
97.03% of 774 companies
in the Biotechnology industry
Industry Median: 3.1 vs BRNS: 236.20

Barinthus Biotherapeutics Revenue per Share Historical Data

The historical data trend for Barinthus Biotherapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Revenue per Share Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue per Share
Get a 7-Day Free Trial 100.44 0.01 1.17 0.02 0.38

Barinthus Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.38 -

Competitive Comparison of Barinthus Biotherapeutics's Revenue per Share

For the Biotechnology subindustry, Barinthus Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's PS Ratio falls into.


;
;

Barinthus Biotherapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Barinthus Biotherapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Revenue Per Share (A: Dec. 2024 )=Revenue (A: Dec. 2024 )/Shares Outstanding (Diluted Average) (A: Dec. 2024 )
=14.969/39.348
=0.38

Barinthus Biotherapeutics's Revenue Per Share for the quarter that ended in Dec. 2024 is calculated as

Revenue Per Share (Q: Dec. 2024 )=Revenue (Q: Dec. 2024 )/Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
=0/40.155
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Barinthus Biotherapeutics  (NAS:BRNS) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Barinthus Biotherapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Barinthus Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Executives
Joseph Scheeren director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright director, officer: Chief Executive Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier officer: Chief Scientific Officer C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown officer: Chief Financial Officer VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths officer: Chief Business Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis officer: Chief Operating Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall officer: Chief Medical Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans officer: Chief Scientific Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov officer: Chief Financial Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE

Barinthus Biotherapeutics Headlines

From GuruFocus

Vaccitech to Present at Upcoming November Investors Conferences

By Value_Insider Value_Insider 11-09-2022